These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27933945)

  • 21. ω3-polyunsaturated fatty acids suppress lipoprotein-associated phospholipase A2 expression in macrophages and animal models.
    Li Z; Ren W; Han X; Liu X; Wang G; Zhang M; Pang D; Ouyang H; Tang X
    Mol Nutr Food Res; 2015 Sep; 59(9):1771-9. PubMed ID: 26018800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target.
    Macphee CH; Nelson J; Zalewski A
    Curr Opin Pharmacol; 2006 Apr; 6(2):154-61. PubMed ID: 16495153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.
    Carlquist JF; Muhlestein JB; Anderson JL
    Expert Rev Mol Diagn; 2007 Sep; 7(5):511-7. PubMed ID: 17892360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of further pyrrolidine trans-lactams as inhibitors of human neutrophil elastase (HNE) with potential as development candidates and the crystal structure of HNE complexed with an inhibitor (GW475151).
    Macdonald SJ; Dowle MD; Harrison LA; Clarke GD; Inglis GG; Johnson MR; Shah P; Smith RA; Amour A; Fleetwood G; Humphreys DC; Molloy CR; Dixon M; Godward RE; Wonacott AJ; Singh OM; Hodgson ST; Hardy GW
    J Med Chem; 2002 Aug; 45(18):3878-90. PubMed ID: 12190311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serendipitous discovery of a potent influenza virus a neuraminidase inhibitor.
    Mohan S; Kerry PS; Bance N; Niikura M; Pinto BM
    Angew Chem Int Ed Engl; 2014 Jan; 53(4):1076-80. PubMed ID: 24339250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target.
    Ali M; Madjid M
    Future Cardiol; 2009 Mar; 5(2):159-73. PubMed ID: 19371190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor.
    MacPhee CH; Moores KE; Boyd HF; Dhanak D; Ife RJ; Leach CA; Leake DS; Milliner KJ; Patterson RA; Suckling KE; Tew DG; Hickey DM
    Biochem J; 1999 Mar; 338 ( Pt 2)(Pt 2):479-87. PubMed ID: 10024526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of Lipoprotein-associated Phospholipase A2 in Serum in Patients With Stage 3-5 Chronic Kidney Disease.
    Wang Y; Li SS; Na SP; Yu CY; Ji Y; Zhao SL; Xie RJ; Bao YS
    Am J Med Sci; 2016 Oct; 352(4):348-353. PubMed ID: 27776715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2.
    Lourida ES; Georgiadis AN; Papavasiliou EC; Papathanasiou AI; Drosos AA; Tselepis AD
    Arthritis Res Ther; 2007; 9(1):R19. PubMed ID: 17326817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipoprotein-associated phospholipase A
    Garg PK; Jorgensen NW; McClelland RL; Jenny NS; Criqui MH; Allison MA; Greenland P; Rosenson RS; Siscovick DS; Cushman M
    Vasc Med; 2017 Feb; 22(1):5-12. PubMed ID: 28215109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).
    Duffey MO; Vos TJ; Adams R; Alley J; Anthony J; Barrett C; Bharathan I; Bowman D; Bump NJ; Chau R; Cullis C; Driscoll DL; Elder A; Forsyth N; Frazer J; Guo J; Guo L; Hyer ML; Janowick D; Kulkarni B; Lai SJ; Lasky K; Li G; Li J; Liao D; Little J; Peng B; Qian MG; Reynolds DJ; Rezaei M; Scott MP; Sells TB; Shinde V; Shi QJ; Sintchak MD; Soucy F; Sprott KT; Stroud SG; Nestor M; Visiers I; Weatherhead G; Ye Y; D'Amore N
    J Med Chem; 2012 Jan; 55(1):197-208. PubMed ID: 22070629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
    Rosenson RS
    Am Heart J; 2008 Mar; 155(3):499.e9-16. PubMed ID: 18294485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
    Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
    Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipoprotein-associated phospholipase A
    Öngen B; Kalkan Uçar S; Levent E; Azarsız E; Koloğlu T; Çoker M; Sözmen E; Sağın FG
    Ann Clin Biochem; 2017 Sep; 54(5):539-547. PubMed ID: 27614353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and structure-activity relationships of novel pyrrolocarbazole lactam analogs as potent and cell-permeable inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).
    Wells GJ; Bihovsky R; Hudkins RL; Ator MA; Husten J
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1151-5. PubMed ID: 16359865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipoprotein-associated phospholipase A(2) and atherosclerosis.
    Wilensky RL; Macphee CH
    Curr Opin Lipidol; 2009 Oct; 20(5):415-20. PubMed ID: 19667981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.
    Sudhir K
    J Clin Endocrinol Metab; 2005 May; 90(5):3100-5. PubMed ID: 15713711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intracellular inhibition of human neutrophil elastase by orally active pyrrolidine-trans-lactams.
    Macdonald SJ; Dowle MD; Harrison LA; Spooner JE; Shah P; Johnson MR; Inglis GG; Clarke GD; Belton DJ; Smith RA; Molloy CR; Dixon M; Murkitt G; Godward RE; Skarzynski T; Singh OM; Kumar KA; Hodgson ST; McDonald E; Hardy GW; Finch H; Humphreys DC; Fleetwood G
    Bioorg Med Chem Lett; 2001 Jan; 11(2):243-6. PubMed ID: 11206469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
    O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipoprotein-associated phospholipase A2 is associated with risk of dementia.
    van Oijen M; van der Meer IM; Hofman A; Witteman JC; Koudstaal PJ; Breteler MM
    Ann Neurol; 2006 Jan; 59(1):139-44. PubMed ID: 16278861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.